191 related articles for article (PubMed ID: 37634012)
1. Genomics of deletion 7 and 7q in myeloid neoplasm: from pathogenic culprits to potential synthetic lethal therapeutic targets.
Mori M; Kubota Y; Durmaz A; Gurnari C; Goodings C; Adema V; Ponvilawan B; Bahaj WS; Kewan T; LaFramboise T; Meggendorfer M; Haferlach C; Barnard J; Wlodarski M; Visconte V; Haferlach T; Maciejewski JP
Leukemia; 2023 Oct; 37(10):2082-2093. PubMed ID: 37634012
[TBL] [Abstract][Full Text] [Related]
2. Cytogenetic deletion maps of hematologic neoplasms: circumstantial evidence for tumor suppressor loci.
Johansson B; Mertens F; Mitelman F
Genes Chromosomes Cancer; 1993 Dec; 8(4):205-18. PubMed ID: 7512363
[TBL] [Abstract][Full Text] [Related]
3. Molecular Pathogenesis of MDS.
Look AT
Hematology Am Soc Hematol Educ Program; 2005; ():156-60. PubMed ID: 16304374
[TBL] [Abstract][Full Text] [Related]
4. Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.
Puda A; Milosevic JD; Berg T; Klampfl T; Harutyunyan AS; Gisslinger B; Rumi E; Pietra D; Malcovati L; Elena C; Doubek M; Steurer M; Tosic N; Pavlovic S; Guglielmelli P; Pieri L; Vannucchi AM; Gisslinger H; Cazzola M; Kralovics R
Am J Hematol; 2012 Mar; 87(3):245-50. PubMed ID: 22190018
[TBL] [Abstract][Full Text] [Related]
5. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases.
Le Beau MM; Espinosa R; Davis EM; Eisenbart JD; Larson RA; Green ED
Blood; 1996 Sep; 88(6):1930-5. PubMed ID: 8822909
[TBL] [Abstract][Full Text] [Related]
6. The significance of CUX1 and chromosome 7 in myeloid malignancies.
Jotte MRM; McNerney ME
Curr Opin Hematol; 2022 Mar; 29(2):92-102. PubMed ID: 35084368
[TBL] [Abstract][Full Text] [Related]
7. Chromosomal deletions in AML.
Nagarajan L
Cancer Treat Res; 2010; 145():59-66. PubMed ID: 20306245
[TBL] [Abstract][Full Text] [Related]
8. CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia.
McNerney ME; Brown CD; Wang X; Bartom ET; Karmakar S; Bandlamudi C; Yu S; Ko J; Sandall BP; Stricker T; Anastasi J; Grossman RL; Cunningham JM; Le Beau MM; White KP
Blood; 2013 Feb; 121(6):975-83. PubMed ID: 23212519
[TBL] [Abstract][Full Text] [Related]
9. The enigma of monosomy 7.
Inaba T; Honda H; Matsui H
Blood; 2018 Jun; 131(26):2891-2898. PubMed ID: 29615405
[TBL] [Abstract][Full Text] [Related]
10. Distinct clinical and biological implications of
Aly M; Ramdzan ZM; Nagata Y; Balasubramanian SK; Hosono N; Makishima H; Visconte V; Kuzmanovic T; Adema V; Nazha A; Przychodzen BP; Kerr CM; Sekeres MA; Abazeed ME; Nepveu A; Maciejewski JP
Blood Adv; 2019 Jul; 3(14):2164-2178. PubMed ID: 31320321
[TBL] [Abstract][Full Text] [Related]
11. [Significance of chromosome 7 abnormalities in myeloid malignancies].
Shi WH; Li X; Chang CK
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1739-43. PubMed ID: 25543507
[TBL] [Abstract][Full Text] [Related]
12. Frequent deletion of p16INK4a/MTS1 and p15INK4b/MTS2 in pediatric acute lymphoblastic leukemia.
Okuda T; Shurtleff SA; Valentine MB; Raimondi SC; Head DR; Behm F; Curcio-Brint AM; Liu Q; Pui CH; Sherr CJ
Blood; 1995 May; 85(9):2321-30. PubMed ID: 7727766
[TBL] [Abstract][Full Text] [Related]
13. [Genetic defects of chromosome 5q and 7q in myeloid neoplasms].
Hosono N
Rinsho Ketsueki; 2019; 60(7):800-809. PubMed ID: 31391370
[TBL] [Abstract][Full Text] [Related]
14. Myeloid malignancies with isolated 7q deletion can be further characterized by their accompanying molecular mutations.
Hartmann L; Haferlach C; Meggendorfer M; Kern W; Haferlach T; Stengel A
Genes Chromosomes Cancer; 2019 Oct; 58(10):698-704. PubMed ID: 30994218
[TBL] [Abstract][Full Text] [Related]
15. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium.
Lerman MI; Minna JD
Cancer Res; 2000 Nov; 60(21):6116-33. PubMed ID: 11085536
[TBL] [Abstract][Full Text] [Related]
16. Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis.
Jerez A; Sugimoto Y; Makishima H; Verma A; Jankowska AM; Przychodzen B; Visconte V; Tiu RV; O'Keefe CL; Mohamedali AM; Kulasekararaj AG; Pellagatti A; McGraw K; Muramatsu H; Moliterno AR; Sekeres MA; McDevitt MA; Kojima S; List A; Boultwood J; Mufti GJ; Maciejewski JP
Blood; 2012 Jun; 119(25):6109-17. PubMed ID: 22553315
[TBL] [Abstract][Full Text] [Related]
17. Chromosome 8p engineering reveals increased metastatic potential targetable by patient-specific synthetic lethality in liver cancer.
Huth T; Dreher EC; Lemke S; Fritzsche S; Sugiyanto RN; Castven D; Ibberson D; Sticht C; Eiteneuer E; Jauch A; Pusch S; Albrecht T; Goeppert B; Candia J; Wang XW; Ji J; Marquardt JU; Nahnsen S; Schirmacher P; Roessler S
Sci Adv; 2023 Dec; 9(51):eadh1442. PubMed ID: 38134284
[TBL] [Abstract][Full Text] [Related]
18. Structural aberrations of chromosome 7 revealed by a combination of molecular cytogenetic techniques in myeloid malignancies.
Brezinová J; Zemanová Z; Ransdorfová S; Pavlistová L; Babická L; Housková L; Melichercíková J; Sisková M; Cermák J; Michalová K
Cancer Genet Cytogenet; 2007 Feb; 173(1):10-6. PubMed ID: 17284364
[TBL] [Abstract][Full Text] [Related]
19. Refined mapping of genomic rearrangements involving the short arm of chromosome 9 in acute lymphoblastic leukemias and other hematologic malignancies.
Dreyling MH; Bohlander SK; Le Beau MM; Olopade OI
Blood; 1995 Sep; 86(5):1931-8. PubMed ID: 7544647
[TBL] [Abstract][Full Text] [Related]
20. -7/7q- syndrome in myeloid-lineage hematopoietic malignancies: attempts to understand this complex disease entity.
Honda H; Nagamachi A; Inaba T
Oncogene; 2015 May; 34(19):2413-25. PubMed ID: 24998854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
